Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Shinji
S
Teramoto
Hiroshi
H
Yamamoto
Yasuhiro
Y
Yamaguchi
Masaki
M
Ishii
Shinichiro
S
Hibi
Haruki
H
Kume
Yasuyoshi
Y
Ouchi
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D000077407:Cilostazol; D018592:Cross-Over Studies; D003680:Deglutition Disorders / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012463:Saliva / Q000187:drug effects / Q000378:metabolism; D020521:Stroke / Q000150:complications*; D013373:Substance P / Q000187:drug effects / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D013373:Substance P; D000077407:Cilostazol; D001241:Aspirin